SCHEMBL2652011

SCHEMBL2652011

NNc1cc[c]cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182584 0.76
SCHEMBL5392914 0.73 NR3C2 (0.41)
SCHEMBL4777990 0.73 CHEK1 (0.37)
SCHEMBL742490 0.71 HCAR3 (0.41)
SCHEMBL2067353 0.71
SCHEMBL1722107 0.71
SCHEMBL27453738 0.70 HRH3 (0.47)
SCHEMBL746385 0.70 HCAR3 (0.43)
SCHEMBL4777917 0.69 IL1B (0.36)
SCHEMBL5896994 0.69 HRH3 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240139354-A1 PARTICLES FUNCTIONALIZED WITH IMAGEABLE RADIOISOTOPES AND METHODS OF MAKING AND USE THEREOF Boston Scientific Medical Device Limited (IE) 2024-05-02 US disclosed
US-11904029-B2 Particles functionalized with imageable radioisotopes and methods of making and use thereof Boston Scientific Medical Device Limited (IE) 2024-02-20 US disclosed
WO-2023091726-A1 INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12) SYROS PHARMACEUTICALS, INC. (US) 2023-05-25 WO disclosed
US-20230117927-A1 Targeted Radiopharmaceutical for Tumor and Its Use in the Imaging-guided Combination Therapy of Targeted Radiotherapy and Immunotherapy BEIJING GILUNTIDE PHARMACEUTICAL CO., LTD. (CN) 2023-04-20 US disclosed
CN-115605467-A PHD inhibitor compounds, compositions and uses thereof 阿克比治疗有限公司(US) 2023-01-13 CN disclosed
CN-115515948-A PHD inhibitor compounds, compositions and uses 阿克比治疗有限公司 2022-12-23 CN disclosed
EP-4100069-A1 PARTICLES FUNCTIONALIZED WITH IMAGEABLE RADIOISOTOPES AND METHODS OF MAKING AND USE THEREOF University Of Virginia Patent Foundation (US) 2022-12-14 EP disclosed
EP-3906947-A1 TARGETED RADIOPHARMACEUTICALS FOR TUMORS, AND COMBINATION THERAPY OF TARGETED RADIOTHERAPY THEREOF AND IMMUNOTHERAPY UNDER GUIDANCE OF IMAGES Peking University (CN) 2021-11-10 EP disclosed
WO-2021158611-A1 PARTICLES FUNCTIONALIZED WITH IMAGEABLE RADIOISOTOPES AND METHODS OF MAKING AND USE THEREOF UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2021-08-12 WO disclosed
US-20210236669-A1 PARTICLES FUNCTIONALIZED WITH IMAGEABLE RADIOISOTOPES AND METHODS OF MAKING AND USE THEREOF UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2021-08-05 US disclosed
WO-2020238800-A1 TARGETED RADIOPHARMACEUTICALS FOR TUMORS, AND COMBINATION THERAPY OF TARGETED RADIOTHERAPY THEREOF AND IMMUNOTHERAPY UNDER GUIDANCE OF IMAGES 北京大学 2020-12-03 WO disclosed
US-7851490-B2 Benzimidazole derivatives and their use for modulating the GABAA receptor complex NEUROSEARCH A/S (DK) 2010-12-14 US disclosed
EP-1877052-B1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH AS (DK) 2009-07-22 EP disclosed
US-20090036493-A1 Benzimidazole Derivatives and Their Use for Modulating the GABA Alpha Receptor Complex ANIONA APS (DK) 2009-02-05 US disclosed
EP-1877052-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2008-01-16 EP disclosed
WO-2006108800-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2006-10-19 WO disclosed